STUDY DATA OF KRAS- AND RAS-UNMUTATED (WILD) TYPE OF COLORECTAL CANCER

Analysis of latest trials, comparing treatment schemes including chemotherapy with anti-EGFR monoclonal antibodies or bevacizumab is presented in this article. The data in these trials is inconsistent, but detailed analysis of FIRE-3 trial allows to distinguish a wild-type RAS patient group that ben...

Full description

Bibliographic Details
Main Author: V. A. Gorbunova
Format: Article
Language:Russian
Published: “ABV-press” Publishing house”, LLC 2015-05-01
Series:Тазовая хирургия и онкология
Subjects:
Online Access:https://ok.abvpress.ru/jour/article/view/122
_version_ 1797759232654704640
author V. A. Gorbunova
author_facet V. A. Gorbunova
author_sort V. A. Gorbunova
collection DOAJ
description Analysis of latest trials, comparing treatment schemes including chemotherapy with anti-EGFR monoclonal antibodies or bevacizumab is presented in this article. The data in these trials is inconsistent, but detailed analysis of FIRE-3 trial allows to distinguish a wild-type RAS patient group that benefits most from chemotherapy with cetuximab or panitumumab as 1st line metastatic colorectal cancer treatment. A final analysis of this patient group in CALGB/SWOG 80 405 trial is pending. The RAS analysis is pivotal for choice of 1st line chemotherapy.
first_indexed 2024-03-12T18:41:27Z
format Article
id doaj.art-152a19bd2269424a9ca33792b46f07cd
institution Directory Open Access Journal
issn 2686-9594
language Russian
last_indexed 2024-03-12T18:41:27Z
publishDate 2015-05-01
publisher “ABV-press” Publishing house”, LLC
record_format Article
series Тазовая хирургия и онкология
spelling doaj.art-152a19bd2269424a9ca33792b46f07cd2023-08-02T07:48:52Zrus“ABV-press” Publishing house”, LLCТазовая хирургия и онкология2686-95942015-05-0151263610.17650/2220-3478-2015-1-26-36106STUDY DATA OF KRAS- AND RAS-UNMUTATED (WILD) TYPE OF COLORECTAL CANCERV. A. Gorbunova0N.N. Blokhin Russian Cancer Research CenterAnalysis of latest trials, comparing treatment schemes including chemotherapy with anti-EGFR monoclonal antibodies or bevacizumab is presented in this article. The data in these trials is inconsistent, but detailed analysis of FIRE-3 trial allows to distinguish a wild-type RAS patient group that benefits most from chemotherapy with cetuximab or panitumumab as 1st line metastatic colorectal cancer treatment. A final analysis of this patient group in CALGB/SWOG 80 405 trial is pending. The RAS analysis is pivotal for choice of 1st line chemotherapy.https://ok.abvpress.ru/jour/article/view/122colorectal cancermonoclonal antibodiescetuximabpanitumumabantiangiogenic drug bevacizumabchemotherapy
spellingShingle V. A. Gorbunova
STUDY DATA OF KRAS- AND RAS-UNMUTATED (WILD) TYPE OF COLORECTAL CANCER
Тазовая хирургия и онкология
colorectal cancer
monoclonal antibodies
cetuximab
panitumumab
antiangiogenic drug bevacizumab
chemotherapy
title STUDY DATA OF KRAS- AND RAS-UNMUTATED (WILD) TYPE OF COLORECTAL CANCER
title_full STUDY DATA OF KRAS- AND RAS-UNMUTATED (WILD) TYPE OF COLORECTAL CANCER
title_fullStr STUDY DATA OF KRAS- AND RAS-UNMUTATED (WILD) TYPE OF COLORECTAL CANCER
title_full_unstemmed STUDY DATA OF KRAS- AND RAS-UNMUTATED (WILD) TYPE OF COLORECTAL CANCER
title_short STUDY DATA OF KRAS- AND RAS-UNMUTATED (WILD) TYPE OF COLORECTAL CANCER
title_sort study data of kras and ras unmutated wild type of colorectal cancer
topic colorectal cancer
monoclonal antibodies
cetuximab
panitumumab
antiangiogenic drug bevacizumab
chemotherapy
url https://ok.abvpress.ru/jour/article/view/122
work_keys_str_mv AT vagorbunova studydataofkrasandrasunmutatedwildtypeofcolorectalcancer